You can buy or sell NLTX and other stocks, options, ETFs, and crypto commission-free!
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Read More Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. The listed name for NLTX is Neoleukin Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 11, After Hours